"Targeting patients at high risk of HF-MACE and advanced heart failure could facilitate the shortest Phase 3 program, the fastest time to market, and the opportunity for the most attractive pricing".
Maybe I'm a bit dumb, but the question that immediately pops into my mind is,
If it is now doing so with these latest amendments to the heart trial, why wasn't the company from the very outset pursuing a course of action that provided "fastest time to market" and '"opportunity for most attractive pricing"?
Why, for all these years (and remember the trial design was submitted to the FDA in 2012), had this trial has been following a path that it turns was not as commercially optimal as its revised version, as indicated yesterday, now is?
Indeed, it was because it involved a large number of patients that the initial trial design, that its value was lauded as it being broad and comprehensive.
Now, comprehensiveness appears to have given way to commercial expedience.
Evidently, on the strength of "no-negative-announcements-ever", both opposing approaches are the right one.
But, of course, like I say, maybe I'm just not very smart.
Expand
(20min delay)